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Abstract. Recombinant human erythropoietin
(rHuEpo) was used to treat the anaemia of four
haemodialysed patients (3 males, 1 female) with
advanced multiple myeloma; the type of serum M
component was IgG kappa in all cases. During the
6-month period preceding rHuEpo therapy the patients
received multiple blood transfusions (range 4-22 units
of packed red cells per patient). After the first month
of treatment haematocrit increased from 23 + 3 (SD) to
32 + 4% and during the last 3 months the maintenance
dose of rHuEpo was 143 + 37 U/kg per week to achieve
a mean haematocrit of 35 + 1%. After introduction of
rHuEpo, blood transfusions were no longer required
and the patients reported an improvement in wellbeing.
No apparent worsening of multiple myeloma has been
observed over the treatment period ranging from 5 to
34 months (cumulative duration of treatment 55
months). Anti-hypertensive therapy was started in one
case and increased in two patients. We conclude that
rHuEpo appears to be effective and safe in treating
anaemia associated with multiple myeloma in patients
requiring haemodialysis.
Key words: erythropoietin; anaemia; multiple myeloma;
haemodialysis
anaemia due to end-stage renal disease alone. More-
over, the effect of rHuEpo on myeloma growth remains
a matter of debate. We report on our experience in
rHuEpo therapy administered in four haemodialysed
patients with stage IIIB multiple myeloma IgG kappa;
three of them were on maintenance haemodialysis,
whereas dialysis was interrupted after 10 weeks in the
last patient because of a partial recovery of renal
function following chemotherapy.
Subjects and methods
From August 1988 to June 1991, four haemodialysed patients
(3 males, 1 female) with multiple myeloma were recruited to
receive rHuEpo treatment for moderate to severe anaemia
requiring regular blood transfusions. The aim of the treat-
ment was to achieve a haematocrit around 35%. rHuEpo
(Eprex®, Cilag, SchafThausen, Switzerland, in three patients;
Recormon®, Boehringer Mannheim, Rotkreuz, Switzerland,
in one patient) was given intravenously at the end of the
dialysis sessions in two patients and subcutaneously in the
two other patients, three times weekly. Haematological para-
meters were assessed monthly; a clinical survey was regularly
performed in all cases to detect any worsening of the multiple
myeloma. Values are given as mean ( ± S D ) .
Introduction
Recently, recombinant human erythropoietin
(rHuEpo) was reported to be effective in treating
anaemia associated with multiple myeloma [1]. Never-
theless, its efficacy and tolerance are poorly docu-
mented in end-stage renal failure patients with multiple
myeloma. In this context the cause of anaemia may be
due both to the effects of multiple myeloma on the
bone marrow and to the low production of endogenous
erythropoietin encountered in end-stage renal disease.
Thus.it is possible that correction of anaemia in these
cases may require larger doses of rHuEpo than in
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Results
All patients presented at stage IIIB [2] of multiple
myeloma and with IgG kappa serum M component.
The clinical and haematological characteristics of the
patients before rHuEpo therapy are summarized in
Table 1. The last course of chemotherapy preceded the
beginning of rHuEpo treatment by 4, 5, and 23 months
in three cases, whereas the remaining patient did not
receive any cancer treatment before starting rHuEpo.
During the 6 months before rHuEpo treatment patients
were given multiple blood transfusions. Plasma ferritin
levels were more than 1000 ug/1 in three cases and
403 ug/1 in the last patient before rHuEpo. The modes
of rHuEpo therapy and haematological response to
treatment are described in Table 2. Mean haematocrit
increased from 23 + 3 to 32 + 4% after the first month
of rHuEpo therapy; during the same time rHuEpo
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Erythropoietin treatment in haemodialysed patients with multiple myeloma 317
doses were 180 + 38 U/kg per week. The cumulative
duration of treatment with rHuEpo was 55 months.
Doses of rHuEpo during the last 3 months studied
were 143 + 37 U/kg per week and were comparable to
the maintenance doses applied over the whole follow-
up period. There was no longer a need for blood
transfusions. All patients reported a rapid improve-
ment in wellbeing. Figure 1 illustrates the evolution of
anaemia before and during rHuEpo therapy in
patient 1. During rHuEpo treatment, antihypertensive
therapy was started in one patient and the increase in
blood pressure required larger doses of antihypertens-
ive drugs in two other cases.
In the first case a second bone marrow biopsy,
performed 25 months after the beginning of rHuEpo,
disclosed only 11 % of abnormal plasma cells; serum
IgG was 23.5 g/1 before rHuEpo and remained stable,
around 30 g/1, during the 30 months following rHuEpo
introduction. In the second patient, serum IgG was
29.5 g/1 before and 9.2 g/1 just after chemotherapy and
plasma exchanges; after 10 months of treatment with
rHuEpo, serum IgG was 17.4 g/1, whereas cancer treat-
ment had been discontinued for more than 1 year. In
the third patient, serum IgG levels of 101 g/1 decreased
to 51 g/1 after a course of chemotherapy (vincristine,
adriamycin, and dexamethasone). Following an exacer-
bation of the disease, chemotherapy was restarted and
linked to plasma exchanges. Six months after the
beginning of rHuEpo and 3 months after the last
plasma exchanges, serum IgG was 42.2 g/1. Finally,
after chemotherapy the last patient recovered a suffi-
cient level of renal function to stop haemodialysis.
rHuEpo was given for 5 months, until the anaemia
resolved spontaneously. The light chains were no
longer detectable in blood and urine at the end of
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Fig. 1. Changes in haematocrit in patient 1 before and during
rHuEpo therapy. Each arrow represents the transfusion of two
packed red-cells. Information on the pretreatment period was retro-
spectively collected during the 6 months preceding rHuEpo therapy.
rHuEpo administration. There were no episodes of
severe hypercalcaemia in any patient, and clinical
examination disclosed no aggravation of the disease
during rHuEpo therapy.
Discussion
Renal failure is generally considered to be an ominous
complication in patients with multiple myeloma [3].
Despite the fact that end-stage renal disease is consid-
ered an indication of a poor prognosis in multiple
myeloma, long-term survival has been observed in
patients requiring renal replacement therapy [4]. Thus
it seems evident that in those patients anaemia must
also be corrected without the hazards inherent in blood
transfusions. The successful administration of rHuEpo
to two patients on regular haemodialysis for end-stage
renal disease due to multiple myeloma has been
reported recently [5]; the duration of the follow up on
rHuEpo treatment was short in these cases. More
recently, Holley et al. published the case of a patient
on continuous peritoneal dialysis who was treated
successfully with rHuEpo, but information about the
evolution of myeloma during the 7-month period of
treatment was lacking [6]. These publications followed
the report of erythropoietin treatment of anaemia
associated with multiple myeloma in patients without
renal failure [1], which did not show any interaction
between the underlying disease and the response to
erythropoietin therapy after 6 months treatment. In
this paper Ludwig et al. reported an 85% success rate
in the correction of anaemia [1]. In the present study
all patients responded dramatically to the treatment
with rHuEpo. Mean doses of rHuEpo remained rela-
tively stable throughout the study period and compar-
able to the doses administered to our group of
haemodialysed patients without malignancy (143 + 37
and 134 + 56 U/kg per week, respectively) [7]. Since
renal function was moderately to severely depressed at
the time of diagnosis of multiple myeloma in two
patients, anaemia might be mainly the consequence of
decreased production of endogenous erythropoietin,
rather than the direct effet of multiple myeloma on the
bone marrow. Nevertheless, the degree of anaemia was
greater than expected at that time to be attributed
solely to renal failure. Furthermore, in the patients 3
and 4 anaemia was already present before the onset of
renal failure. Thus it seems reasonable to attribute the
cause of anaemia to both renal and haematological
problems during rHuEpo therapy.
Treatment with rHuEpo produced an obvious
improvement in quality of life and ended the need for
blood transfusions. Clinical and haematological mon-
itoring did not disclose a stimulatory effect of rHuEpo
on the malignant clone over the study period ranging
from 5 to 34 months. Conversely, the activity of the
disease remained stable, despite abstention from
chemotherapy by three patients, during that time, when
taking into account the changes in IgG levels and the
degree of bone marrow infiltration by abnormal plasma
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cells when available. This is at odds with the case
reported by Rogers et al., which exhibited a temporary
increase in urinary excretion of lambda light chains,
reversed to the previous level after cessation of treat-
ment with rHuEpo [8]. It would in theory be surprising
if rHuEpo had favoured myeloma growth because
there is no evidence of a stimulatory effect of this
substance on B lineage cells, even though some authors
have shown effects on non-erythroid haemopoietic
progenitor cells [9,10]. On the contrary, the rather
quiet course of the myeloma raises the possibility that
avoiding blood transfusions might have decreased the
growth rate of the aberrant B cell clone. Effectively,
the immunosuppressive nature of blood transfusions
may decrease non-specific immune response and thus
further enhance the susceptibility of patients with
myeloma to infectious complications [11,12] and per-
haps also the rate of tumour growth [12]. Such a
hypothesis, however, needs confirmation. We conclude
that in our experience rHuEpo treatment in haemodia-
lysed patients suffering from multiple myeloma is safe,
well tolerated, and as effective as in patients on haemo-
dialysis without malignancy.
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